$1.13 EPS Expected for Eli Lilly and Co (LLY) This Quarter

Brokerages predict that Eli Lilly and Co (NYSE:LLY) will announce earnings of $1.13 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Eli Lilly and’s earnings. The lowest EPS estimate is $1.10 and the highest is $1.17. Eli Lilly and reported earnings of $0.98 per share during the same quarter last year, which would indicate a positive year over year growth rate of 15.3%. The business is expected to announce its next earnings results before the market opens on Tuesday, April 24th.

On average, analysts expect that Eli Lilly and will report full-year earnings of $4.87 per share for the current year, with EPS estimates ranging from $4.82 to $4.91. For the next fiscal year, analysts anticipate that the business will report earnings of $5.29 per share, with EPS estimates ranging from $5.16 to $5.43. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Eli Lilly and.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. During the same period in the prior year, the firm earned $0.95 EPS. The company’s revenue was up 7.0% compared to the same quarter last year.

LLY has been the subject of a number of analyst reports. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and increased their price target for the stock from $85.52 to $115.00 in a research note on Friday, January 5th. Goldman Sachs lowered Eli Lilly and from a “buy” rating to a “neutral” rating and increased their price target for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Jefferies Group set a $100.00 price target on Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Credit Suisse Group lowered Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 price target for the company. in a research note on Monday, January 22nd. Finally, BMO Capital Markets increased their price target on Eli Lilly and from $73.00 to $74.00 and gave the stock an “underperform” rating in a research note on Thursday, February 1st. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $93.16.

Shares of LLY stock opened at $80.12 on Friday. Eli Lilly and has a 52-week low of $73.69 and a 52-week high of $89.09. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $87,341.06, a price-to-earnings ratio of 18.72, a price-to-earnings-growth ratio of 1.49 and a beta of 0.26.

In related news, insider Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares of the company’s stock, valued at approximately $334,901.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joshua L. Smiley sold 3,000 shares of the stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $79.20, for a total transaction of $237,600.00. Following the completion of the transaction, the chief financial officer now directly owns 20,029 shares of the company’s stock, valued at approximately $1,586,296.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,261 shares of company stock valued at $1,225,085. 0.11% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in LLY. Cambridge Investment Research Advisors Inc. lifted its stake in Eli Lilly and by 6.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 106,014 shares of the company’s stock worth $8,954,000 after purchasing an additional 6,830 shares during the last quarter. Colonial Trust Advisors lifted its stake in Eli Lilly and by 35.0% in the fourth quarter. Colonial Trust Advisors now owns 65,467 shares of the company’s stock worth $5,529,000 after purchasing an additional 16,973 shares during the last quarter. Xact Kapitalforvaltning AB lifted its stake in Eli Lilly and by 7.8% in the fourth quarter. Xact Kapitalforvaltning AB now owns 200,443 shares of the company’s stock worth $16,929,000 after purchasing an additional 14,586 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in Eli Lilly and by 2.7% in the fourth quarter. Handelsbanken Fonder AB now owns 309,140 shares of the company’s stock worth $26,110,000 after purchasing an additional 8,200 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in Eli Lilly and by 3.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 224,857 shares of the company’s stock worth $18,991,000 after purchasing an additional 7,162 shares during the last quarter. 77.66% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This report was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.chaffeybreeze.com/2018/04/17/1-13-eps-expected-for-eli-lilly-and-co-lly-this-quarter.html.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply